Data / Research funding / Hepatitis - C
Hepatitis - C: 261 NIH awards ($385M) to 117 organizations
261 NIH awards ($385M) in the NIH spending category Hepatitis - C, to 117 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
261 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Expanding HOPE Liver Transplantation: Understanding Opportunistic Infection and Cancer Risk | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $18,807,472 | August 1, 2018 | August 31, 2030 | DURAND, CHRISTINE MARIE | reporter.nih.gov |
| AIDS Linked to the IntraVenous Experience (ALIVE) Study | NIH | National Institute on Drug Abuse | 2021 to 2025 | $12,226,379 | January 1, 2014 | May 31, 2030 | MEHTA, SHRUTI H | reporter.nih.gov |
| Mays Cancer Center at UT Health SA | NIH | National Cancer Institute | 2021 to 2025 | $11,193,809 | August 1, 1997 | July 31, 2026 | ZHENG, LEI | reporter.nih.gov |
| Reagent Program for HIV and other Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,735,388 | October 15, 2023 | January 13, 2024 | RASHID, SUJATHA | reporter.nih.gov |
| Addressing risk through Community Treatment for Infectious disease and Opioid use disorder Now (ACTION) among justice-involved populations | NIH | National Institute on Drug Abuse | 2021 to 2025 | $10,550,278 | September 30, 2020 | July 31, 2026 | SPRINGER, SANDRA ANN | reporter.nih.gov |
| Health Economics of Substance Use Disorder, HCV, and HIV Treatment: Supporting Financial Sustainability, Advanced Methods, and Knowledge Translation | NIH | National Institute on Drug Abuse | 2021 to 2025 | $8,690,640 | July 15, 2015 | April 30, 2030 | SCHACKMAN, BRUCE R | reporter.nih.gov |
| A trial of transplanting Hepatitis C-viremic kidneys into Hepatitis C-Negative kidney recipients (THINKER-NEXT) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $7,767,541 | April 15, 2021 | March 31, 2027 | SCHAUBEL, DOUGLAS EARL | reporter.nih.gov |
| Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism | NIH | National Institute on Drug Abuse | 2021 to 2024 | $6,868,774 | April 1, 2020 | January 31, 2026 | STRATHDEE, STEFFANIE A. | reporter.nih.gov |
| Johns Hopkins HIV Clinical Cohort | NIH | National Institute on Drug Abuse | 2021 to 2024 | $5,955,256 | July 1, 2014 | March 31, 2026 | MOORE, RICHARD DOUGLAS | reporter.nih.gov |
| Rational design and efficacy testing of vaccines against HCV | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,737,237 | May 5, 2022 | April 30, 2027 | FUERST, THOMAS R | reporter.nih.gov |
| A Randomized Controlled Trial of Prophylaxis with Direct-acting Antivirals for Kidney Transplantation from Hepatitis C virus-infected donor to Uninfected Recipients (PREVENT-HCV) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,162,956 | March 25, 2022 | February 28, 2027 | DURAND, CHRISTINE MARIE | reporter.nih.gov |
| Integrating Addiction and Infectious Diseases Services into Primary Care in Rural Settings | NIH | National Institute on Drug Abuse | 2021 to 2025 | $4,664,222 | August 1, 2021 | May 31, 2027 | ALTICE, FREDERICK LEWIS | reporter.nih.gov |
| Increasing Access to Hepatitis C Treatment in Opioid Endemic Rural Areas: the Kentucky Viral Hepatitis Treatment (KeY Treat) Study | NIH | National Institute on Drug Abuse | 2021 to 2023 | $4,371,481 | September 30, 2018 | July 31, 2025 | HAVENS, JENNIFER R | reporter.nih.gov |
| The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,204,220 | May 15, 2015 | June 30, 2030 | FLEXNER, CHARLES W. | reporter.nih.gov |
| Integrating HCV services into HIV programs for PWID in India | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,184,487 | July 8, 2019 | June 30, 2025 | MEHTA, SHRUTI H | reporter.nih.gov |
| Making Better Decisions: Policy Modeling for AIDS and Drug Abuse | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,865,844 | September 25, 2022 | January 31, 2029 | OWENS, DOUGLAS K | reporter.nih.gov |
| Spatio-temporal Methods for Surveillance of the Opioid Syndemic | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,748,657 | September 1, 2025 | August 31, 2029 | KLINE, DAVID M | reporter.nih.gov |
| Conduct Synthesis and Acquire Batches of Compounds for Subsequent Biological In Vitro and In Vivo Testing | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,702,250 | April 1, 2024 | March 31, 2025 | MIDDLETON, MARK | reporter.nih.gov |
| NIH: Spatial Models of Intrahepatic Hepatitis Virus Propagation in Humans | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,593,236 | February 7, 2022 | January 31, 2027 | RIBEIRO, RUY M | reporter.nih.gov |
| Structural and Mechanistic basis for RNA Silencing | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,507,599 | August 1, 2018 | July 31, 2028 | MACRAE, IAN JOHN | reporter.nih.gov |
| Combating Related Epidemics in HCV through Simplified Testing and Treatment (CREST) | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,411,692 | September 24, 2025 | August 31, 2030 | NAGGIE, SUSANNA | reporter.nih.gov |
| Evaluation of a community-based education, navigation, and support (CENS) intervention to reduce opioid-related harms among military veterans | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,379,762 | September 30, 2021 | July 31, 2027 | BENNETT, ALEXANDER S | reporter.nih.gov |
| Promoting remote and secondary risk prevention services in rural settings | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,349,340 | September 30, 2022 | July 31, 2027 | PHO, MAI TUYET | reporter.nih.gov |
| A geospatial analysis of hotspots and targeted injection settings pilot intervention for HIV prevention among people who inject drugs in Baltimore, Maryland | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,292,995 | July 1, 2020 | May 31, 2027 | LATKIN, CARL A | reporter.nih.gov |
| A smartphone-enabled point-of-care HCV Ag diagnostic using catalytic nanoparticles and AI-enhanced image processing | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $3,284,055 | September 9, 2022 | June 30, 2027 | SHAFIEE, HADI | reporter.nih.gov |
| Implementation of telemedicine and social network driven HIV service uptake for comprehensive HIV service integration in rural syringe service programs | NIH | National Institute on Drug Abuse | 2023 to 2025 | $3,234,132 | August 1, 2023 | May 31, 2028 | FALADE-NWULIA, OLUWASEUN | reporter.nih.gov |
| Collaborative Integration of HCV Molecular Virology and Mathematical Modeling | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,185,361 | August 1, 2010 | May 31, 2027 | UPRICHARD, SUSAN L. | reporter.nih.gov |
| Impact of harm reduction care in HIV clinical settings on stigma and health outcomes for PLWH who use drugs | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,152,106 | September 30, 2021 | June 30, 2027 | HAWK, MARY ELIZABETH | reporter.nih.gov |
| Molecular and structural characterization of broadly neutralizing anti-HCV antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,115,747 | February 15, 2023 | January 31, 2028 | BAILEY, JUSTIN RICHARD | reporter.nih.gov |
| The Impact of HCV Treatment in HIV/HCV coinfected and HCV monoinfected Incarcerated Persons on HCV Elimination | NIH | National Institute on Drug Abuse | 2021 to 2024 | $3,045,888 | September 30, 2020 | August 31, 2025 | IRVIN, RISHA | reporter.nih.gov |
| A Randomized Trial to Test the Efficacy of a Partner Navigation Intervention for HCV Treatment among Young Adult People who Inject Drugs | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,017,588 | June 1, 2022 | March 31, 2027 | MORRIS, MEGHAN D | reporter.nih.gov |
| Anchimerically Activatable Anti-Zika/Dengue ProTides | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,946,770 | August 1, 2021 | July 31, 2026 | WAGNER, CARSTON R. | reporter.nih.gov |
| Dynamic Strategies for the clinical management of HIV disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,926,858 | August 9, 2012 | May 31, 2028 | HERNAN, MIGUEL | reporter.nih.gov |
| Kinetic and structural basis for SARS-CoV-2 RNA-dependent RNA polymerase specificity and inhibition | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,889,190 | July 16, 2021 | June 30, 2027 | JOHNSON, KENNETH ALLEN | reporter.nih.gov |
| Cardiovascular Risk Reduction in an Aging HIV-Infected Population: The Impact of HCV Co-Infection | NIH | National Institute on Aging | 2021 to 2023 | $2,851,326 | May 1, 2019 | January 31, 2025 | TRIANT, VIRGINIA ATHENA | reporter.nih.gov |
| Computational modeling for HCV vaccine trial design and optimal vaccine-based combination interventions | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,842,189 | November 1, 2021 | October 31, 2026 | DAHARI, HAREL | reporter.nih.gov |
| Recruitment for the efficacy trial of Tele-Harm Reduction in a federally qualified health center operated syringe services program | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,609,496 | May 1, 2021 | April 30, 2026 | TOOKES, HANSEL EMORY | reporter.nih.gov |
| Leveraging HCV Phylogenetic Networks to Prevent HIV and Other Blood Borne Infections Among People Who Inject Drugs | NIH | National Institute on Drug Abuse | 2021 | $2,520,000 | June 1, 2021 | May 31, 2026 | AKIYAMA, MATTHEW | reporter.nih.gov |
| Understanding human antibody responses to chronic viral hepatitis C | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,488,538 | January 17, 2022 | December 31, 2026 | LAW, MANSUN | reporter.nih.gov |
| Immune correlates of protection against hepacivirus persistence. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,486,556 | April 1, 2021 | September 30, 2025 | KAPOOR, AMIT | reporter.nih.gov |
| Digital, Community-Led, Social Action Initiative to Reduce Opioid Vulnerability and HIV/HCV in Rural Areas of the Midwest and Appalachia | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,437,500 | May 1, 2019 | April 30, 2025 | ALBARRACIN, DOLORES | reporter.nih.gov |
| A binational cohort of the intersection between substance use, HIV, and associated comorbidities among people who inject drugs in San Diego, CA | NIH | National Institute on Drug Abuse | 2025 | $2,437,310 | July 15, 2025 | May 31, 2030 | STRATHDEE, STEFFANIE A. | reporter.nih.gov |
| Defining the role of the RNA modification N6-methyladenosine during Flaviviridae virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,403,276 | June 1, 2016 | January 31, 2027 | HORNER, STACY MICHELLE | reporter.nih.gov |
| Kentucky Outreach Service Kiosk (KyOSK): Reducing Overdose, Hepatitis C, and Other Drug-related Risks in Rural Appalachia through Health Kiosks | NIH | National Institute on Drug Abuse | 2022 to 2025 | $2,359,307 | August 15, 2022 | June 30, 2027 | YOUNG, APRIL MARIE | reporter.nih.gov |
| Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,331,243 | August 1, 2020 | June 30, 2025 | SHAPIRO, MARTIN F. | reporter.nih.gov |
| Evaluation of a persuasive health communication intervention designed to increase HIV/HCV screening among emergency departments patients who currently, formerly or never injected drugs | NIH | National Institute on Drug Abuse | 2022 to 2024 | $2,264,864 | September 30, 2022 | July 31, 2027 | MERCHANT, ROLAND C | reporter.nih.gov |
| Integrated Care for Addiction, HIV and HCV Research and Education (ICAHRE) | NIH | National Institute on Drug Abuse | 2021 to 2025 | $2,234,611 | July 1, 2017 | June 30, 2027 | STEIN, MICHAEL D | reporter.nih.gov |
| Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort) | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,227,803 | April 1, 2019 | March 31, 2026 | CRANE, HEIDI M. | reporter.nih.gov |
| New insights into the functional diversity of the hepatic antiviral T cell response during hepacivirus infection in vivo | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,227,294 | June 1, 2022 | May 31, 2027 | BILLERBECK, EVA | reporter.nih.gov |
| Mechanistic function of HCV NS5A targeted by the potent inhibitors | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,218,100 | February 1, 2020 | January 31, 2026 | YI, MINKYUNG | reporter.nih.gov |
| Etiology of Persistent Microalbuminuria in Nigeria | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,202,068 | July 1, 2021 | May 31, 2026 | WESTER, C. WILLIAM | reporter.nih.gov |
| Estimating the population size of persons who inject drugs in New York | NIH | National Institute on Drug Abuse | 2021 to 2022 | $2,200,197 | June 1, 2021 | December 13, 2022 | BRADLEY, HEATHER | reporter.nih.gov |
| Understanding the Multilevel Drivers of Liver Cancer Disparities | NIH | National Cancer Institute | 2021 to 2023 | $2,174,412 | August 16, 2019 | July 31, 2025 | SHARIFF-MARCO, SALMA | reporter.nih.gov |
| Assessing performance of a Hepatitis C Emergency Department (HepC-END) Screening Tool | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,102,922 | September 15, 2023 | July 31, 2028 | PARK, HAESUK | reporter.nih.gov |
| Responding to the Increase in Substance Use, HIV, HCV, and Overdose in New England (RISE-NE) | NIH | National Institute on Drug Abuse | 2025 | $2,076,525 | August 15, 2025 | May 31, 2030 | BAZZI, ANGELA ROBERTSON | reporter.nih.gov |
| Genetic Viral and Host Adaptations to Breach Species Barriers of HCV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,049,912 | July 1, 2013 | December 31, 2028 | PLOSS, ALEXANDER | reporter.nih.gov |
| Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugs | NIH | National Institute on Drug Abuse | 2021 to 2023 | $2,039,441 | January 15, 2019 | December 31, 2025 | THOMAS, DAVID L | reporter.nih.gov |
| Estimating the cost of peer specialists providing comprehensive healthcare services at a syringe services program | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,007,015 | June 1, 2023 | March 31, 2028 | TOOKES, HANSEL EMORY | reporter.nih.gov |
| Rapid point-of-care molecular test for HCV VL | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,996,224 | September 1, 2021 | March 31, 2027 | FISHER, JAY KENNETH | reporter.nih.gov |
| Leveraging the plasma virome as a biological indicator of HIV risk and transmission networks among people who inject drugs | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,994,072 | June 1, 2023 | March 31, 2028 | KANDATHIL, ABRAHAM | reporter.nih.gov |
| Understanding and Improving the Effectiveness of Public Health Laboratory Networks for Infectious Diseases in Ghana | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,975,313 | March 11, 2019 | February 28, 2025 | SCHROEDER, LEE FREDERICK | reporter.nih.gov |
| A renewable and genetically tractable human stem cell-derived multicellular platform for the study of fibrotic liver diseases | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,974,527 | March 1, 2021 | February 28, 2025 | RICE, CHARLES M | reporter.nih.gov |
| Peer-based Retention of people who Use Drugs in Rural Research (PROUD-R2) | NIH | National Center for Advancing Translational Sciences | 2021 to 2023 | $1,971,059 | September 18, 2018 | July 31, 2024 | KORTHUIS, PHILIP TODD | reporter.nih.gov |
| San Diego Cirrhosis Clinical Research Network | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,949,305 | September 9, 2021 | July 31, 2027 | LOOMBA, ROHIT | reporter.nih.gov |
| Developing a renewable and dissectible human liver for the study of HBV/HCV infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,932,000 | August 18, 2022 | July 31, 2027 | WU, XIANFANG | reporter.nih.gov |
| The UW Medical Student Addiction Research (MedStAR) Program to Address Substance Use and Disorders in Urban and Rural Communities in Five Western States | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,882,544 | May 1, 2020 | April 30, 2030 | TSUI, JUDITH | reporter.nih.gov |
| Role of HCV exosomes in intercellular communication | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,877,240 | April 15, 2020 | February 28, 2026 | HAHN, YOUNG S. | reporter.nih.gov |
| Modeling Viral and T Lymphocyte Dynamics | NIH | Office of the Director, National Institutes of Health | 2021 to 2024 | $1,866,528 | December 23, 2019 | November 30, 2025 | PERELSON, ALAN S | reporter.nih.gov |
| Ending transmission of HIV, HCV, and STDs and overdose in rural communities of people who inject drugs (ETHIC) | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,836,801 | August 15, 2017 | July 31, 2023 | PHO, MAI TUYET | reporter.nih.gov |
| Testing of Drug Combinations For Mycobacterium tuberculosis (MTB) in Mice | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,831,148 | September 1, 2022 | November 30, 2025 | SLAYDEN, RICHARD | reporter.nih.gov |
| Harnessing the power of peer navigation and mHealth to reduce health disparities in Appalachia | NIH | National Institute of Nursing Research | 2021 to 2024 | $1,805,022 | August 27, 2020 | March 21, 2025 | RHODES, SCOTT D | reporter.nih.gov |
| Rapid, Point-of-Care Diagnostics for Hepatitis C Virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,799,981 | August 12, 2022 | August 12, 2025 | UNGEWITTER, ERICA | reporter.nih.gov |
| Non-immunosuppressive Sanglifehrin Analogs as Therapeutic Agents for Viral Hepatitis-induced Liver Damage Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,783,750 | April 1, 2020 | March 31, 2026 | GALLAY, PHILIPPE ANDRE | reporter.nih.gov |
| UC San Diego Raising Advancement and Parity for Infectious Disease Researchers (RAPID) Faculty Development Program | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,778,757 | August 10, 2020 | July 31, 2030 | TREJO, JOANN | reporter.nih.gov |
| Development of standardized immunoassays and virus panels for HCV vaccine research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,651,974 | July 23, 2021 | June 30, 2025 | BAILEY, JUSTIN RICHARD | reporter.nih.gov |
| Next generation quantitative HCV drug resistance assay | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $1,611,097 | March 1, 2018 | June 30, 2025 | WAGNER, RICHARD | reporter.nih.gov |
| Animal Model to study heterogeneous outcomes of HCV Infection and Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,575,922 | June 1, 2024 | April 30, 2029 | KAPOOR, AMIT | reporter.nih.gov |
| Collaborative Justice-Involved Research and Training Program on Substance Use and HIV at Brown University Health | NIH | National Institute on Drug Abuse | 2021 to 2025 | $1,575,185 | June 1, 2014 | December 31, 2029 | BECKWITH, CURT G | reporter.nih.gov |
| Changes in Bone Quality, Sarcopenia and Fat Distribution in HIV/HCV Patients after HCV Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,553,826 | December 1, 2017 | November 30, 2024 | LO RE, VINCENT | reporter.nih.gov |
| Engaging People Who Use Drugs in Harm Reduction Service Delivery: An Intravention to Reduce Risk of HIV, HCV, Overdose, and Injection-related Infections in Rural Appalachia | NIH | National Institute on Drug Abuse | 2024 | $1,533,697 | September 30, 2024 | August 31, 2026 | YOUNG, APRIL MARIE | reporter.nih.gov |
| The Epidemiology of the Weiss Cohort Project | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,531,257 | August 15, 2020 | June 30, 2023 | WEISS, STANLEY H | reporter.nih.gov |
| Point-of-care Nucleic Acid Amplification Test for pangenomic Hepatitis C diagnosis in outpatient clinics | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,528,985 | July 3, 2024 | May 31, 2029 | POSNER, JONATHAN D | reporter.nih.gov |
| O-glycoproteins in the progression of liver disease | NIH | National Cancer Institute | 2021 to 2023 | $1,525,161 | July 1, 2019 | June 30, 2024 | GOLDMAN, RADOSLAV | reporter.nih.gov |
| Molecular mechanisms of nucleic acid machines | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,520,008 | June 1, 2020 | May 31, 2026 | ENEMARK, ERIC | reporter.nih.gov |
| Building on Needle Exchange to Optimize HIV Prevention/Treatment | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,506,924 | September 15, 2017 | March 31, 2025 | LUCAS, GREGORY M | reporter.nih.gov |
| SBIR PHASE II Point-of-Care HCV Detection | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $1,500,000 | September 15, 2023 | September 14, 2026 | QI, HONG | reporter.nih.gov |
| The Epidemiology of the Weiss Cohort Project | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,471,222 | August 15, 2020 | June 30, 2027 | WEISS, STANLEY H | reporter.nih.gov |
| Oregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) Study Cost Extension | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,441,353 | August 15, 2017 | July 31, 2023 | KORTHUIS, PHILIP TODD | reporter.nih.gov |
| Universal HCV screening in pregnancy: Examining testing uptake and HCV care | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,439,607 | September 30, 2024 | July 31, 2029 | KAPADIA, SHASHI | reporter.nih.gov |
| Perfluoroalkyl Substances (PFASs) and Liver Cancer Risk in the United States | NIH | National Cancer Institute | 2024 to 2025 | $1,426,107 | July 1, 2022 | June 30, 2027 | ZHANG, XUEHONG | reporter.nih.gov |
| Predict, Detect, Diagnose: Confronting Outbreaks of HIV and Other Infectious Diseases Among People Who Use Drugs | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,422,136 | September 1, 2024 | May 31, 2029 | GONSALVES, GREGG STEVEN | reporter.nih.gov |
| Estimating the population size of persons who inject drugs in New York | NIH | National Institute on Drug Abuse | 2023 to 2024 | $1,422,069 | October 1, 2022 | January 31, 2026 | BRADLEY, HEATHER | reporter.nih.gov |
| Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE) | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,415,827 | August 15, 2017 | July 31, 2023 | YOUNG, APRIL MARIE | reporter.nih.gov |
| Dynamics of antigen specific B and Tfh responses during acute and chronic HCV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,411,254 | December 13, 2017 | November 30, 2024 | GRAKOUI, ARASH | reporter.nih.gov |
| Integrating low-cost and versatile technologies to achieve colorimetric HCV and HIV detection from whole blood | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,401,526 | August 15, 2024 | June 30, 2029 | MYERS, DAVID RICHARD | reporter.nih.gov |
| Hepatitis C Virus Trafficking in Hepatocytes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,372,358 | March 5, 2019 | February 28, 2025 | RANDALL, GLENN C | reporter.nih.gov |
| SELECTION OF VACCINE ANTIGENS FOR PROTECTION FROM HEPATITIS C VIRUS INFECTION | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,349,865 | July 1, 2020 | April 30, 2026 | RAY, RANJIT | reporter.nih.gov |
| Project ACCESS: Advancing Access to HIV/HCV Testing Through Transformation in Syringe Services Programs: A Cluster Randomized Trial | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,343,426 | July 1, 2024 | April 30, 2029 | BARTHOLOMEW, TYLER SCOTT | reporter.nih.gov |
| Viral Determinants of Chronic Hepacivirus Infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,331,080 | June 1, 2024 | April 30, 2029 | KAPOOR, AMIT | reporter.nih.gov |
| T cells in HCV/HIV co-infection | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,296,998 | March 1, 2018 | December 31, 2023 | LAUER, GEORG MICHAEL | reporter.nih.gov |
| Reducing morbidity and mortality from overdose, HIV, and hepatitis C in opioid-using persons | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,262,543 | September 1, 2018 | June 30, 2024 | BRAITHWAITE, RONALD SCOTT | reporter.nih.gov |
| HIV, HCV, Hippo, and Liver Disease Progression | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,239,696 | November 3, 2017 | October 31, 2024 | CHUNG, RAYMOND T | reporter.nih.gov |
| Persistent hepatitis C virus replication and immunity in pregnancy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,233,787 | February 1, 2012 | May 31, 2025 | WALKER, CHRISTOPHER M. | reporter.nih.gov |
| Manipulation of lipid metabolism in (+)RNA virus replication | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,230,000 | June 7, 2023 | May 31, 2028 | RANDALL, GLENN C | reporter.nih.gov |
| A Multi-site Multi-Setting RCT of Integrated HIV Prevention and HCV Care for PWID | NIH | National Institute on Drug Abuse | 2022 | $1,217,167 | September 30, 2017 | March 12, 2025 | METSCH, LISA R | reporter.nih.gov |
| Active HCV diagnosis to support prevention of HCC in LMICs | NIH | National Cancer Institute | 2024 to 2025 | $1,208,204 | August 9, 2024 | July 31, 2029 | MCFALL, SALLY MAUREEN | reporter.nih.gov |
| A Cluster RCT to Increase HIV Testing in Substance Use Treatment Programs | NIH | National Institute on Drug Abuse | 2021 | $1,188,364 | September 1, 2016 | July 31, 2025 | METSCH, LISA R | reporter.nih.gov |
| Testing of a Novel Inhaled Clofazimine (CFZ) Dry Powder Formulation in a Mouse Model of Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,164,080 | August 1, 2023 | June 30, 2025 | ENDSLEY, JANICE | reporter.nih.gov |
| Effects of State Laws to Reduce Opioid Diversion on Transitions to Injection Drug Use and HIV/HCV Transmission | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,137,366 | April 1, 2018 | December 31, 2023 | DICKSON-GOMEZ, JULIA B | reporter.nih.gov |
| Drug Injection Surveillance and Care Enhancement for Rural Northern New England (DISCERNNE) | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,131,736 | August 15, 2017 | July 31, 2023 | FRIEDMANN, PETER D | reporter.nih.gov |
| Structure-Based Vaccine Design for Hepatits C Virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,120,994 | June 1, 2017 | May 31, 2023 | FUERST, THOMAS R | reporter.nih.gov |
| Harnessing big data to arrest the HIV/HCV/opioid syndemic in the rural and urban South | NIH | National Institute on Drug Abuse | 2023 to 2025 | $1,115,625 | June 1, 2023 | March 31, 2028 | REBEIRO, PETER F | reporter.nih.gov |
| Roles for microRNA-122 and circular RNAs in flavivirus RNA amplification | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,099,000 | February 15, 2006 | April 30, 2025 | SARNOW, PETER | reporter.nih.gov |
| Tracking HIV Infection & Alcohol Abuse CNS Comorbidity with Neuroimaging | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 | $1,088,145 | September 30, 2007 | August 31, 2023 | PFEFFERBAUM, ADOLF | reporter.nih.gov |
| The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for HCV Trial | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,050,850 | March 1, 2018 | December 31, 2024 | HAUKOOS, JASON | reporter.nih.gov |
| The mitochondrial aspects of health disparity of hepatocellular carcinoma in Hispanic population | NIH | National Cancer Institute | 2023 to 2025 | $1,040,371 | July 1, 2023 | June 30, 2026 | BAI, YIDONG | reporter.nih.gov |
| Individual, Network and Spatial Drivers of HIV and HCV among PWID in India | NIH | National Institute on Drug Abuse | 2021 | $1,035,149 | September 1, 2016 | May 31, 2023 | SOLOMON, SUNIL SUHAS | reporter.nih.gov |
| Epigenetic Heterogeneity as a Driver of Liver Disease and Cancer | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2022 | $1,012,300 | August 15, 2018 | May 31, 2024 | ROBERTSON, KEITH D | reporter.nih.gov |
| Implementing a Community-Based Response to the Opioid Epidemic in Rural Ohio - Supplement | NIH | National Institute on Drug Abuse | 2021 to 2022 | $1,004,587 | August 15, 2017 | July 31, 2023 | MILLER, WILLIAM C | reporter.nih.gov |
| Advancing a novel potent double anti-HCV nucleoside analog combination treatment for the OUD population to the clinic | NIH | National Institute on Drug Abuse | 2021 | $995,102 | September 15, 2019 | August 31, 2023 | KLUMPP, KLAUS | reporter.nih.gov |
| qHTS of Patient Derived HCC Models to Identify Novel Probes/Therapeutic Agents | NIH | National Cancer Institute | 2021 to 2022 | $964,654 | March 1, 2019 | August 31, 2023 | JOHNSTON, PAUL A. | reporter.nih.gov |
| Host response and liver disease in a hepatitis C-like virus rat model | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $964,504 | February 1, 2018 | January 31, 2024 | KAPOOR, AMIT | reporter.nih.gov |
| Community-based, client-centered prevention homes to address the rural opioid epidemic | NIH | National Institute on Drug Abuse | 2021 to 2022 | $941,278 | August 15, 2017 | July 31, 2023 | WESTERGAARD, RYAN PATRICK | reporter.nih.gov |
| California Hub for HIV/STI/SUD Prevention Research with Reentry Populations | NIH | National Institute on Drug Abuse | 2025 | $932,421 | May 15, 2024 | July 31, 2029 | HARAWA, NINA THAWATA | reporter.nih.gov |
| Rapid point of care Hepatitis C virus detection using a long-lasting luminescent cascade signal amplification | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $884,453 | November 22, 2024 | October 31, 2029 | SHAFIEE, HADI | reporter.nih.gov |
| The Landscape of Serious Infections following Kidney Transplantation in People Living with HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $846,608 | August 19, 2021 | July 31, 2026 | WERBEL, WILLIAM | reporter.nih.gov |
| California Hub for HIV/STI/SUD Prevention Research with Reentry Populations | NIH | National Institute on Drug Abuse | 2024 | $814,282 | May 15, 2024 | April 30, 2026 | HARAWA, NINA THAWATA | reporter.nih.gov |
| DAT 18-06 Feasibility and Acceptability of HIV, HCV, and Opioid Use Disorder Services in Syringe Service Programs | NIH | National Institute on Drug Abuse | 2021 | $800,234 | September 1, 2009 | July 31, 2022 | SCHACKMAN, BRUCE R | reporter.nih.gov |
| Structural Basis for Antiviral Drug Mitochondrial Toxicity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $782,460 | March 1, 2018 | February 28, 2025 | YIN, YUHUI | reporter.nih.gov |
| Point-of-care magnetofluidic HCV diagnostic using thermally responsive valves | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $781,351 | March 1, 2024 | January 31, 2028 | WHITE, IAN M | reporter.nih.gov |
| A Hybrid Implementation-Effectiveness Study of the Pharmacist, Physician, and Patient Navigator Collaborative Care Model to cure Hepatitis C among persons who use drugs with housing insecurity | NIH | National Institute on Drug Abuse | 2025 | $777,497 | August 15, 2025 | April 30, 2030 | TSUI, JUDITH | reporter.nih.gov |
| Human factors-designed triple test for HIV, HBV, and HCV infection in whole blood using target amplification, signal amplification, and crumpled graphene biosensor readout | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $776,341 | September 16, 2025 | August 31, 2030 | CUNNINGHAM, BRIAN T. | reporter.nih.gov |
| Perinatal care as a venue to reduce opioid overdoses and hepatitis C virus incidence (PreVenT OD HCV) | NIH | National Institute on Drug Abuse | 2022 to 2025 | $769,863 | July 1, 2022 | June 30, 2027 | EPSTEIN, RACHEL LEE | reporter.nih.gov |
| Uncovering the Biochemical Mechanisms of Riboregulatory Interaction Involving the Hepatitis C Virus 3'X RNA | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $753,221 | September 1, 2024 | July 31, 2029 | HOLMSTROM, ERIK D | reporter.nih.gov |
| Integrating Assisted Partner Services and Phylogenetics for HIV and HCV Prevention | NIH | National Institute on Drug Abuse | 2021 | $738,109 | May 15, 2017 | February 29, 2024 | FARQUHAR, CAREY | reporter.nih.gov |
| Mitigating the Outcomes Associated with the Injection Drug Use Epidemic in Southern Appalachia | NIH | National Institute on Drug Abuse | 2021 | $732,149 | August 15, 2017 | July 31, 2024 | ZULE, WILLIAM A | reporter.nih.gov |
| Developing a predictive in silico toolkit for modeling NK cell responses against RNA virus infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $728,188 | September 5, 2019 | August 31, 2025 | DAS, JAYAJIT | reporter.nih.gov |
| Mechanism of telomere attrition and premature T cell aging during HCV infection | NIH | National Institute on Aging | 2022 to 2023 | $704,290 | March 1, 2022 | February 28, 2025 | ZHAO, JUAN | reporter.nih.gov |
| HIV, HCV, and gender effects on Liver, Bone, and Vascular Health | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $686,762 | July 15, 2013 | June 30, 2025 | TIEN, PHYLLIS C | reporter.nih.gov |
| Long-term Effects of IDU, HIV, HCV and the Impact of HCV Cure on Immune Activation and Liver Fibrosis in Aging Women | NIH | National Institute on Drug Abuse | 2021 | $672,140 | April 15, 2017 | February 28, 2025 | KOVACS, ANDREA A.Z. | reporter.nih.gov |
| Evaluation of a persuasive health communication intervention designed to increase HIV/HCV screening among emergency departments patients who currently, formerly or never injected drugs | NIH | National Institute on Drug Abuse | 2025 | $663,802 | September 30, 2022 | July 31, 2027 | MERCHANT, ROLAND C | reporter.nih.gov |
| HIV-induced monocyte and macrophage perturbations driving liver fibrogenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 | $650,980 | August 1, 2022 | July 31, 2024 | ALATRAKCHI, NADIA | reporter.nih.gov |
| Strategies to reduce serious bacterial infections and overdose among people who inject drugs | NIH | National Institute on Drug Abuse | 2021 to 2024 | $636,091 | June 15, 2020 | May 31, 2026 | BAROCAS, JOSHUA ADAM | reporter.nih.gov |
| Roles for virus-derived circular RNAs during RNA virus infections | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $634,198 | February 15, 2006 | August 31, 2026 | SARNOW, PETER | reporter.nih.gov |
| Integrated Care for Hepatitis C: Current Uptake & Impact on Future Treatment | NIH | National Institute on Drug Abuse | 2021 to 2023 | $603,469 | August 1, 2019 | July 31, 2025 | KAPADIA, SHASHI | reporter.nih.gov |
| Ending HIV and Taming HCV and Overdose Among Puerto Rican PWID in New York City: The Ganchero Intervention | NIH | National Institute on Drug Abuse | 2023 to 2025 | $583,902 | June 1, 2023 | April 30, 2027 | GELPI-ACOSTA, CAMILA | reporter.nih.gov |
| Mentoring Multidisciplinary Patient-Oriented Research in Liver Disease | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2023 | $580,533 | August 1, 2013 | September 30, 2025 | KHALILI, MANDANA | reporter.nih.gov |
| PRECISE: accessible sample-to-answer RT-PCR detection of hepatitis C infection from whole blood | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $575,356 | August 8, 2025 | July 31, 2030 | SIA, SAMUEL K | reporter.nih.gov |
| 2/3 COMpAAAS Tripartite: ART-CC, KP, and VA | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 | $573,066 | September 15, 2017 | August 31, 2024 | SILVERBERG, MICHAEL J | reporter.nih.gov |
| Mechanism and Predictors of Neurocognitive Impairment in HIV Infection | NIH | National Institute of Mental Health | 2021 to 2023 | $567,960 | March 1, 2020 | February 29, 2024 | O'CONNOR, ERIN E | reporter.nih.gov |
| Mentorship in research on opioid use disorder treatment and HIV prevention | NIH | National Institute on Drug Abuse | 2023 to 2025 | $554,412 | August 15, 2023 | July 31, 2028 | FOX, AARON D | reporter.nih.gov |
| Analysis of immunity, viral adaptation and pathogenesis in a new mouse model of HCV-related rodent hepacivirus infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $554,390 | March 15, 2017 | February 28, 2023 | RICE, CHARLES M | reporter.nih.gov |
| Treatment outcomes and comorbidity in HIV-infected IDU | NIH | National Institute on Drug Abuse | 2021 to 2024 | $544,168 | April 1, 2014 | August 31, 2025 | LUCAS, GREGORY M | reporter.nih.gov |
| A single biosensors for the simultaneous molecular detection of HIV and Hepatitis B and C viruses at resource-limited settings | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $537,619 | March 1, 2025 | February 29, 2028 | CHUMBIMUNI-TORRES, KARIN | reporter.nih.gov |
| Contextual risk factors for hepatitis C among young persons who inject drugs | NIH | National Institute on Drug Abuse | 2021 | $525,951 | September 1, 2017 | June 30, 2024 | BOODRAM, BASMATTEE | reporter.nih.gov |
| Mechanisms of hepatic innate immune activation by HCV | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $523,114 | December 15, 2016 | November 30, 2022 | GALE, MICHAEL | reporter.nih.gov |
| Immune correlates of long-term success with DAA therapy in HCV/HIV infected people who inject drugs | NIH | National Institute on Drug Abuse | 2021 | $519,525 | September 15, 2017 | May 31, 2023 | KOTTILIL, SHYAMASUNDARAN | reporter.nih.gov |
| 3/3 COMpAAAS Tripartite: ART-CC, KP, and VA | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 | $519,196 | September 20, 2017 | August 31, 2022 | JUSTICE, AMY CAROLINE | reporter.nih.gov |
| RNA homodimerization strand displacement pathways to extended duplexes: Atomistic details for a mechanistic paradigm to identify unique antiviral targets for current and emerging viral pandemics | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $507,121 | August 21, 2025 | July 31, 2028 | EVANSECK, JEFFREY D | reporter.nih.gov |
| Impact of Hepatitis C and HIV coinfection on biological aging and hepatocellular carcinoma risk | NIH | Fogarty International Center | 2022 to 2023 | $500,450 | July 1, 2022 | June 30, 2025 | DEBES, JOSE DANIEL | reporter.nih.gov |
| Advance Care Coordination and Enhanced Linkage and Retention Among Transitional Re-Entrants Living | NIH | National Institute on Drug Abuse | 2021 to 2022 | $498,000 | April 1, 2020 | March 31, 2024 | AKIYAMA, MATTHEW | reporter.nih.gov |
| Immunization strategies to elicit broadly neutralizing antibodies against HCV | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $498,000 | July 6, 2020 | July 31, 2024 | FLYAK, ANDREW I | reporter.nih.gov |
| Development of a Novel Split Enzyme Diagnostic Platform for Use at the Point of Care | NIH | National Institute of Biomedical Imaging and Bioengineering | 2024 to 2025 | $498,000 | September 1, 2024 | August 31, 2027 | MAJORS, CATHERINE E. | reporter.nih.gov |
| Exploring Mechanisms of Hepatitis C Virus-Associated Xerostomia | NIH | National Institute of Dental & Craniofacial Research | 2024 to 2025 | $491,236 | June 20, 2024 | May 31, 2027 | MALDONADO-ORTIZ, JOSÉ ORLANDO | reporter.nih.gov |
| Defining successful intrahepatic CD4+ T cell responses against the hepatitis C virus | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $489,389 | March 21, 2025 | February 28, 2030 | WALKER, CHRISTOPHER M. | reporter.nih.gov |
| Implementing a Low-Threshold Hepatitis C Treatment in a Jail Setting | NIH | National Institute on Drug Abuse | 2024 to 2025 | $487,686 | September 15, 2024 | August 31, 2027 | BERK, JUSTIN | reporter.nih.gov |
| Modulation of RNA modifications by RNA viruses | NIH | National Institute of General Medical Sciences | 2021 | $481,269 | September 20, 2018 | August 31, 2024 | PAGER, CARA THERESIA | reporter.nih.gov |
| Analyses of the Antiviral and Antifibrotic Mechanisms of Action of NS5A and Cyclophilin Inhibitors | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $481,250 | January 16, 2017 | December 31, 2022 | GALLAY, PHILIPPE ANDRE | reporter.nih.gov |
| Screening of Glycan Markers in Serum for Early Detection of HCC in Different Etiologies of Disease | NIH | National Cancer Institute | 2021 | $473,414 | May 9, 2018 | April 30, 2023 | LUBMAN, DAVID M. | reporter.nih.gov |
| Developing a Service Planning Tool to Address the Combined HIV and Opioid Epidemics | NIH | National Institute on Drug Abuse | 2025 | $461,491 | August 1, 2025 | July 31, 2027 | ZELENEV, ALEXEI | reporter.nih.gov |
| Characterization of plasma virome in people who inject drugs to identify early transmission networks of HIV and other bloodborne infections | NIH | National Institute on Drug Abuse | 2021 to 2022 | $450,313 | May 15, 2021 | April 30, 2024 | KANDATHIL, ABRAHAM | reporter.nih.gov |
| Elucidating How Tri-phosphatase DUSP11 Controls HCV Infection and Hepatocyte Inflammation | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $449,504 | August 1, 2018 | July 31, 2023 | SULLIVAN, CHRISTOPHER S. | reporter.nih.gov |
| Roles for hepatitis C virus-derived circular RNAs in infected cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $432,925 | July 1, 2021 | June 30, 2024 | SARNOW, PETER | reporter.nih.gov |
| A Novel Janus Bead Blood Assay for Point-of-Care Assessment of HCV Viral Load and Associated Liver Damage | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $430,375 | July 8, 2024 | May 31, 2026 | CHANG, HSUEH-CHIA | reporter.nih.gov |
| A sequence-independent approach for attenuating hepaciviruses | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $429,000 | November 7, 2022 | October 31, 2024 | KAPOOR, AMIT | reporter.nih.gov |
| 1/3 Collaborative Research in HIV/AIDS, Alcohol, and Related Comorbidities (COMpAAAS) Tripartite: ART-CC, KP, and VA | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 | $427,571 | September 20, 2017 | August 31, 2024 | STERNE, JONATHAN | reporter.nih.gov |
| Rapid detection of Hepatitis C virus using CRISPR/Cas | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $419,375 | September 1, 2021 | August 31, 2024 | JAIN, PIYUSH K | reporter.nih.gov |
| Rapid point-of-care detection of Hepatitis C viral RNA using multiplexed CRISPR/Cas platforms | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $419,375 | May 1, 2022 | April 30, 2025 | JAIN, PIYUSH K | reporter.nih.gov |
| Comparative Animal Models of Viral Hepatitis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $419,103 | May 17, 2019 | February 29, 2024 | TOMLINSON, JOY E | reporter.nih.gov |
| A Novel Human Virus in Patients with Cryptogenic Liver Disease | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $416,625 | August 1, 2023 | July 31, 2025 | FAN, XIAOFENG | reporter.nih.gov |
| Paper-Based Nucleic Acid Amplification Test for Rapid Diagnosis of Hepatitis C Viral Infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $406,490 | February 1, 2022 | January 31, 2025 | DONG, WEN-JI | reporter.nih.gov |
| Mentored research in solid organ transplantation: outcomes using organs from Hepatitis C virus infected donors for uninfected recipients | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $402,498 | July 1, 2019 | August 31, 2024 | REESE, PETER PHILIP | reporter.nih.gov |
| Rapid at-home Detection for Serologic Status of Hepatitis C Virus (HCV) Infection | NIH | National Cancer Institute | 2022 | $400,000 | September 19, 2022 | September 18, 2023 | QI, HONG | reporter.nih.gov |
| One Test, One Kit for Identifying Active Hepatitis C Virus (HCV) Infection at Home | NIH | National Cancer Institute | 2022 | $400,000 | September 19, 2022 | September 18, 2023 | ZHOU, JASON | reporter.nih.gov |
| Computational discovery of effective hepatitis C intervention strategies | NIH | National Institute of General Medical Sciences | 2021 | $398,579 | August 15, 2017 | July 31, 2024 | DAHARI, HAREL | reporter.nih.gov |
| Reaching the hardest of the hard-to-reach | NIH | National Institute on Drug Abuse | 2023 | $396,652 | January 1, 2016 | August 31, 2022 | SOLOMON, SUNIL SUHAS | reporter.nih.gov |
| A Simple at-home test for rapid and accurate screening for Hepatitis C Virus (HCV) exposure | NIH | National Cancer Institute | 2022 | $393,833 | September 20, 2022 | September 19, 2023 | MANOHAR, JOHN | reporter.nih.gov |
| Identification of Novel Bioactive Lipid Metabolites for Predicting Liver-related Outcomes in Persons Co-Infected with HIV and HCV | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $391,834 | March 15, 2017 | February 29, 2024 | NAGGIE, SUSANNA | reporter.nih.gov |
| NANOG-positive cancer stem cells in liver oncogenesis induced by alcohol and HCV | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 | $371,250 | September 1, 2017 | May 31, 2023 | MACHIDA, KEIGO | reporter.nih.gov |
| Integration of buprenorphine into a multi-component harm reduction program fro people who inject drugs in Kampala, Uganda | NIH | National Institute on Drug Abuse | 2021 to 2022 | $367,193 | September 1, 2020 | July 31, 2024 | DICKSON-GOMEZ, JULIA B | reporter.nih.gov |
| Proyecto Vida: Developing an HIV, HCV and opioid use MOST intervention for persons who inject drugs along the Texas-Mexico Border | NIH | National Institute on Drug Abuse | 2024 to 2025 | $366,673 | September 30, 2024 | August 31, 2029 | LUDWIG-BARRON, NATASHA | reporter.nih.gov |
| Trauma-informed, resilience-based telehealth intervention for improving HIV prevention and HCV care for persons who inject drugs in the Deep South | NIH | National Institute on Drug Abuse | 2024 to 2025 | $366,441 | February 15, 2024 | January 31, 2029 | HAIDER, MOHAMMAD RIFAT | reporter.nih.gov |
| Engaging Young People who Inject Drugs into HCV and HIV Care | NIH | National Institute on Drug Abuse | 2021 to 2022 | $362,944 | May 1, 2018 | April 30, 2024 | ASSOUMOU, SABRINA A | reporter.nih.gov |
| The role of injection partnerships and preferences for reducing HCV risk: Giving a voice to young women in rural Appalachia | NIH | National Institute on Drug Abuse | 2021 to 2023 | $358,694 | March 15, 2019 | August 11, 2023 | LANCASTER, KATHRYN ELIZABETH | reporter.nih.gov |
| Prospects for hepatitis C elimination in networks of people who inject drugs through improvements in the care continuum | NIH | National Institute on Drug Abuse | 2023 to 2024 | $357,224 | February 1, 2023 | January 31, 2025 | ZHU, LIN | reporter.nih.gov |
| Understanding the Determinants of Racial/Ethnic Disparities in Liver Cancer and Chronic Liver Disease in Understudied and High-Risk Populations | NIH | National Cancer Institute | 2021 | $350,258 | March 6, 2018 | August 31, 2023 | SETIAWAN, VERONICA WENDY | reporter.nih.gov |
| Effect of Hepatitis C Virus Eradication on Chronic Kidney Disease Progression | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $345,200 | July 1, 2018 | April 30, 2024 | SISE, MEGHAN E. | reporter.nih.gov |
| Emory R38 Research Training Program | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $344,760 | August 1, 2018 | July 31, 2024 | OFOTOKUN, IGHOVWERHA | reporter.nih.gov |
| Hepatitis C virus infection and mechanism of liver disease progression | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $340,875 | April 1, 2017 | March 31, 2024 | RAY, RANJIT | reporter.nih.gov |
| NIAID Division of AIDS (DAIDS) Chemotherapeutic Agents Repository | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $304,084 | December 15, 2023 | December 14, 2025 | reporter.nih.gov | |
| RAPID POINT OF CARE TESTS FOR HEPATITIS C VIRUS | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $300,000 | August 31, 2021 | August 30, 2022 | ZHOU, JASON | reporter.nih.gov |
| POINT-OF-CARE HCV DETECTION | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $300,000 | August 31, 2021 | August 30, 2022 | QI, HONG | reporter.nih.gov |
| DEVELOPMENT OF RAPID POINT-OF-CARE DIAGNOSTICS FOR HEPATITIS C VIRUS | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $300,000 | August 27, 2021 | August 27, 2022 | FAN, XIOAMIN | reporter.nih.gov |
| Precision Glycoengineering of an HCV Envelope-Based Nanoparticle Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $300,000 | July 17, 2023 | June 30, 2025 | HORRIGAN, STEPHEN KEVIN | reporter.nih.gov |
| Long-Acting Antiviral Implant for the Treatment of HCV | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $299,997 | September 1, 2024 | August 31, 2025 | WRIGHT, MELISSA | reporter.nih.gov |
| A Simple Multiplexed Platform for Self-Administered HIV and Hepatitis B Testing | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $299,982 | August 1, 2024 | July 31, 2028 | NG, RAINER | reporter.nih.gov |
| A RAPID, POINT-OF-CARE SENSOR FOR DETECTION OF HEPATITIS C VIRUS INFECTIONS | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $299,979 | August 27, 2021 | August 27, 2022 | LAICER, CASTRO | reporter.nih.gov |
| Development of an Ultrasensitive, Rapid and Easy-to-Use At-Home Molecular Test for HCV, HBV AND HIV | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $299,961 | August 1, 2024 | April 30, 2025 | JANGAM, SUJIT | reporter.nih.gov |
| RAPID POINT OF CARE DIAGNOSTICS FOR HCV | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $299,957 | September 16, 2021 | September 15, 2022 | SUBRAMANIAN, KUMAR | reporter.nih.gov |
| HEPATITIS C VIRUS DIAGNOSTICS | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $299,889 | September 16, 2021 | September 15, 2022 | ALDEN, JONATHAN | reporter.nih.gov |
| An Easy-to-Use, Low-Cost Triplex RDT for the Simultaneous Diagnosis of HBV, HCV, AND HIV Infection, Compatible with Field Use in LMICS and At-Home Use in the US | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $299,659 | August 1, 2024 | July 31, 2025 | BIAMONTE, MARCO ANTONIO | reporter.nih.gov |
| Pont-of-use Acute HIV Infection Diagnostic for Substance Using Populations | NIH | National Institute on Drug Abuse | 2023 | $289,274 | July 1, 2020 | June 30, 2025 | LINNES, JACQUELINE | reporter.nih.gov |
| Rapid point-of-care molecular test for HCV VL | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $288,729 | September 1, 2021 | August 31, 2022 | FISHER, JAY KENNETH | reporter.nih.gov |
| Generating fast-on rate reagents for lateral flow assays to detect HCV | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $275,606 | April 13, 2023 | March 31, 2025 | KAY, BRIAN KENNETH | reporter.nih.gov |
| Rapid Antigen Test for Diagnosis of Active HCV Infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $272,133 | June 18, 2025 | May 31, 2027 | HERRERA, BOBBY BROOKE F | reporter.nih.gov |
| Medicaid Prior Authorization Policies for Chronic Hepatitis C Treatment in Vulnerable Populations | NIH | National Institute on Drug Abuse | 2021 to 2022 | $259,055 | May 1, 2018 | April 30, 2023 | PARK, HAESUK | reporter.nih.gov |
| Detecting drug-resistant HBV and HCV variants using a DDS probe array | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $253,385 | February 2, 2021 | January 31, 2022 | SHAFER, DAVID A | reporter.nih.gov |
| Prospects for hepatitis C elimination in networks of people who inject drugs through improvements in the care continuum | NIH | National Institute on Drug Abuse | 2025 | $249,000 | February 1, 2023 | May 31, 2028 | ZHU, LIN | reporter.nih.gov |
| A Citizen Science Approach to Increase HIV/STI/HCV Testing and Substance Use Service Utilization Among Survivors of Sex Trafficking Living in New York City | NIH | National Institute on Drug Abuse | 2025 | $246,012 | September 1, 2025 | June 30, 2028 | DAVIS, ALISSA | reporter.nih.gov |
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24) | NIH | National Institute on Drug Abuse | 2021 to 2022 | $244,072 | April 15, 2012 | March 31, 2024 | SULKOWSKI, MARK SEBASTIAN | reporter.nih.gov |
| Rheumatoid factor and cryoglobulinemia in chronic viral infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $241,875 | December 18, 2019 | November 30, 2022 | LAW, MANSUN | reporter.nih.gov |
| How Hepatitis C Virus Regulates Desmosterol to Affect RNA Replication: a New Virus-Host Interaction | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $236,190 | January 1, 2020 | December 31, 2022 | YANG, PRISCILLA LI-NING | reporter.nih.gov |
| Patterns of HIV, hepatitis C, and sexually transmitted infections (STI) co-infection among rural people who inject drugs in the context of an ongoing HIV outbreak | NIH | National Institute on Drug Abuse | 2025 | $232,625 | September 15, 2025 | August 31, 2027 | SCHNEIDER, KRISTIN ERICA | reporter.nih.gov |
| Design of immunologically intact soluble HCV E1E2 complexes using transmembrane-mimic scaffolds | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $230,519 | June 1, 2020 | May 31, 2022 | PIERCE, BRIAN G. | reporter.nih.gov |
| Improving the Diagnosis and Fibrosis Risk Assessment of Nonalcoholic Fatty Liver Disease in Primary Care Patients with Abnormal Liver Chemistries | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2023 | $226,438 | May 15, 2022 | August 31, 2024 | SCHREINER, ANDREW DAVID | reporter.nih.gov |
| Elucidating Hepatitis C Infection as a Risk Factor for Coronary Heart Disease in HIV-Infected Patients | NIH | National Heart, Lung, and Blood Institute | 2021 | $225,513 | June 1, 2017 | May 31, 2023 | BAGCHI, SHASHWATEE | reporter.nih.gov |
| Rapid point-of-care test for hepatitis C virus (HCV) core antigen to screen active HCV infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $224,018 | April 1, 2021 | February 28, 2022 | LAN, TIAN | reporter.nih.gov |
| Harnessing interpersonal connections for improved patient-oriented research for people who inject drugs (PWID) | NIH | National Institute on Drug Abuse | 2025 | $216,724 | July 15, 2025 | June 30, 2030 | MORRIS, MEGHAN D | reporter.nih.gov |
| Pilot Study of a Community-Pharmacy Model to Expand Access to Medications to Treat and Prevent Hepatitis C, Opioid Use Disorders, Overdose and HIV Among Persons Who Inject Drugs | NIH | National Institute on Drug Abuse | 2021 | $214,590 | August 1, 2019 | June 30, 2023 | TSUI, JUDITH | reporter.nih.gov |
| Development of a single-cell antibody cloning protocol for isolation of hepatitis C virus-specific broadly neutralizing antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $204,688 | March 6, 2020 | February 28, 2023 | BAILEY, JUSTIN RICHARD | reporter.nih.gov |
| Factors Responsible for Liver Recovery After Successful Treatment of Hepatitis C. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $199,800 | September 15, 2017 | August 31, 2023 | DUNN, WINSTON | reporter.nih.gov |
| A Phase 1 PK and Safety Study of Velpatasvir/Sofosbuvir for Chronic Hepatitis C Infection in Pregnant Women | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 | $197,741 | June 1, 2020 | May 31, 2024 | CHAPPELL, CATHERINE | reporter.nih.gov |
| Understanding the mediating role of adherence in risk factors for unfavorable outcomes from tuberculosis treatment | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $169,500 | December 26, 2023 | October 31, 2026 | FRANKE, MOLLY FORREST | reporter.nih.gov |
| Drug Treatment as Disease Prevention: Reducing Sexually Transmitted Infection Risk among Women Who Use Drugs | NIH | National Institute on Drug Abuse | 2024 to 2025 | $152,000 | May 15, 2024 | April 30, 2027 | SCHEIDELL, JOY DANIELLE | reporter.nih.gov |
| The Influence of Spatial Proximity to Sterile Syringe Sources and Secondary Syringe Exchange on HCV Risk Among Rural People Who Inject Drugs | NIH | National Institute on Drug Abuse | 2021 to 2023 | $150,540 | July 6, 2020 | June 2, 2024 | ROMO, ERIC | reporter.nih.gov |
| Buprenorphine, Hepatitis C Virus and Their Relationship in Rural US Populations | NIH | National Institute on Drug Abuse | 2021 to 2023 | $144,323 | April 1, 2020 | March 31, 2024 | BROOK, DANIEL | reporter.nih.gov |
| Colliding Epidemics During an Opioid Crisis: Impact of the COVID-19 Pandemic on Determinants of HIV and HCV Transmission Among People Who Inject Drugs | NIH | National Institute on Drug Abuse | 2021 to 2023 | $140,482 | September 1, 2021 | August 31, 2024 | PATEL, ESHAN UDAY | reporter.nih.gov |
| Immunization strategies to elicit broadly neutralizing antibodies against HCV | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $129,465 | July 6, 2020 | June 30, 2022 | FLYAK, ANDREW I | reporter.nih.gov |
| Development of a Novel Split Enzyme Diagnostic Platform for Use at the Point of Care | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 | $107,871 | July 1, 2023 | June 30, 2024 | MAJORS, CATHERINE E. | reporter.nih.gov |
| Hepacivirus control by vaccine-elicited T cells. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $102,788 | December 17, 2018 | December 16, 2022 | HARTLAGE, ALEX STEPHEN | reporter.nih.gov |
| MyD88-dependent B cell dysfunction and autoimmunity during chronic liver disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $100,781 | March 16, 2017 | February 28, 2023 | THAPA, MANOJ | reporter.nih.gov |
| Functional implications of structural heterogeneity in a viral RNA translation initiation element | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $98,512 | September 15, 2024 | September 14, 2027 | SEGAR, KATHERINE | reporter.nih.gov |
| Defining Immune Dysfunction in Chronic Hepacivirus Infection at Single Cell Resolution | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $98,512 | August 1, 2024 | July 31, 2027 | BOBROWSKI, TESIA | reporter.nih.gov |
| Developing, Implementing, and Pilot Testing an Informed Decision Aid for Opioid Agonist Therapies for Prisoners in Ukraine | NIH | National Institute on Drug Abuse | 2021 to 2023 | $93,730 | January 16, 2022 | January 15, 2024 | BROMBERG, DANIEL J | reporter.nih.gov |
| Investigating the role of intrahepatic plasma cells in the clearance of HCV infection: implications for rational vaccine design | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $78,040 | December 1, 2024 | June 30, 2026 | GRIDLEY, JOHN | reporter.nih.gov |
| Risk Environment Effects on Ontological Security Among People Who Use Drugs: An Ethnographic Study | NIH | National Institute on Drug Abuse | 2021 to 2023 | $77,487 | January 1, 2022 | June 21, 2023 | GOLDSHEAR, JESSE LLOYD | reporter.nih.gov |
| Simulation Modeling to Support the Public Health Response to the Opioid Crisis in North America | NIH | National Institute on Drug Abuse | 2021 to 2023 | $74,115 | June 1, 2021 | July 31, 2024 | SCHACKMAN, BRUCE R | reporter.nih.gov |
| HIV and Liver Disease Conference | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $65,001 | July 1, 2006 | March 31, 2024 | SHERMAN, KENNETH E | reporter.nih.gov |
| Implications of reinfection for Hepatitis C elimination among HIV-infected and uninfected people who inject drugs | NIH | National Institute on Drug Abuse | 2021 | $52,412 | July 1, 2020 | June 30, 2023 | GRANTZ, KYRA H | reporter.nih.gov |
| The effect of opioids, stimulants, and the simultaneous use of both on the hepatitis C virus (HCV) cascade of care in rural communities in the United States | NIH | National Institute on Drug Abuse | 2022 to 2023 | $51,995 | May 3, 2022 | May 7, 2023 | ESTADT, ANGELA T | reporter.nih.gov |
| Substance Use Modeling Consortium Workshop to Support the Public Health Response to the Overdose Crisis in North America | NIH | National Institute on Drug Abuse | 2024 to 2025 | $49,812 | June 1, 2021 | July 31, 2029 | LINAS, BENJAMIN P. | reporter.nih.gov |
| Quantifying the Effects of Alcohol Use on Antiviral Adherence | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 | $32,306 | September 1, 2020 | August 31, 2022 | SALAH, LANA M | reporter.nih.gov |
| HIV-DART 2024 | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $30,000 | November 8, 2024 | October 31, 2025 | SCHINAZI, RAYMOND FELIX | reporter.nih.gov |
| Preclinical Services for HIV Therapeutics: QA/QC Plan and Task Order Initiation Meeting | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $20,635 | June 1, 2021 | September 30, 2021 | GARCIA-MARTINEZ, J. VICTOR | reporter.nih.gov |
| Preclinical Services for HIV Therapeutics: QA/QC Plan and Task Order Initiation Meeting | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $18,894 | April 15, 2021 | August 14, 2021 | MCDONALD, JACOB | reporter.nih.gov |
| Preclinical Services for HIV Therapeutics: QA/QC Plan and Task Order Initiation Meeting | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $17,195 | April 15, 2021 | August 14, 2021 | TALTON, JAMES | reporter.nih.gov |
| HEP DART 2021: FRONTIERS IN DRUG DEVELOPMENT FOR HEPATOLOGY | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $12,000 | November 4, 2021 | October 31, 2022 | SCHINAZI, RAYMOND FELIX | reporter.nih.gov |
| Preclinical Services for HIV Therapeutics: QA/QC Plan and Task Order Initiation Meeting | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $10,582 | April 15, 2021 | August 14, 2021 | SUBBIAN, SELVAKUMAR | reporter.nih.gov |
| Preclinical Services for HIV Therapeutics: QA/QC Plan and Task Order Initiation Meeting | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $8,746 | April 15, 2021 | August 14, 2021 | RAJUR, RAJ | reporter.nih.gov |
| Preclinical Services for HIV Therapeutics: QA/QC Plan and Task Order Initiation Meeting | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $4,382 | April 15, 2021 | August 14, 2021 | ERB, DENNIS | reporter.nih.gov |
| How Hepatitis C Virus Regulates Desmosterol to Affect RNA Replication: a New Virus-Host Interaction | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1 | January 1, 2020 | June 1, 2021 | YANG, PRISCILLA LI-NING | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Johns Hopkins University | Baltimore, MD | 24 | $74.6 million | 0 | $0 |
| Yale University | New Haven, CT | 7 | $19.1 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 5 | $15.1 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 6 | $13.9 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 2 | $12.2 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 4 | $12.2 million | 0 | $0 |
| American Type Culture Collection | Manassas, VA | 1 | $10.7 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 4 | $9.7 million | 0 | $0 |
| Research Inst Nationwide Children's Hosp | Columbus, OH | 9 | $9.3 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 5 | $8.5 million | 0 | $0 |
| University of Washington | Seattle, WA | 7 | $7.9 million | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 4 | $7.9 million | 0 | $0 |
| University of Chicago | Chicago, IL | 4 | $7.8 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 6 | $7 million | 0 | $0 |
| Stanford University | Stanford, CA | 6 | $6.6 million | 0 | $0 |
| Loyola University Chicago | Maywood, IL | 3 | $6.4 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 5 | $6.4 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 4 | $6.2 million | 0 | $0 |
| Duke University | Durham, NC | 3 | $6.2 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 4 | $5.8 million | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 2 | $5.6 million | 0 | $0 |
| Triad National Security, LLC | Los Alamos, NM | 2 | $5.5 million | 0 | $0 |
| Emory University | Atlanta, GA | 8 | $4.8 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 2 | $4.2 million | 0 | $0 |
| University of Texas Med BR Galveston | Galveston, TX | 3 | $4.2 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 2 | $4.1 million | 0 | $0 |
| Starks Associates, Inc. | Buffalo, NY | 1 | $3.7 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 2 | $3.4 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 2 | $3.4 million | 0 | $0 |
| New York University | New York, NY | 1 | $3.4 million | 0 | $0 |
| University of Texas at Austin | Austin, TX | 2 | $3.3 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 2 | $3.3 million | 0 | $0 |
| University of Florida | Gainesville, FL | 4 | $3.2 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 3 | $3 million | 0 | $0 |
| Harvard University D/b/a Harvard School of Public Health | Boston, MA | 1 | $2.9 million | 0 | $0 |
| Rockefeller University | New York, NY | 2 | $2.5 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 2 | $2.4 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 2 | $2.4 million | 0 | $0 |
| Redbud Labs, Inc. | Durham, NC | 2 | $2.3 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 1 | $2.2 million | 0 | $0 |
| Georgia State University | Atlanta, GA | 1 | $2.2 million | 0 | $0 |
| Qoolabs, Inc. | Carlsbad, CA | 3 | $2.2 million | 0 | $0 |
| Saint Louis University | Saint Louis, MO | 3 | $2.1 million | 0 | $0 |
| Baebies, Inc. | Durham, NC | 2 | $2.1 million | 0 | $0 |
| Princeton University | Princeton, NJ | 1 | $2 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 1 | $1.9 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 1 | $1.9 million | 0 | $0 |
| Colorado State University | Fort Collins, CO | 1 | $1.8 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 2 | $1.7 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 2 | $1.7 million | 0 | $0 |
| Medosome Biotec, LLC | Alachua, FL | 1 | $1.6 million | 0 | $0 |
| Miriam Hospital | Providence, RI | 1 | $1.6 million | 0 | $0 |
| Ohio State University | Columbus, OH | 4 | $1.6 million | 0 | $0 |
| Rbhs-New Jersey Medical School | Newark, NJ | 2 | $1.5 million | 0 | $0 |
| Georgetown University | Washington, DC | 1 | $1.5 million | 0 | $0 |
| Univ of Arkansas for Med Scis | Little Rock, AR | 1 | $1.5 million | 0 | $0 |
| Medical College of Wisconsin | Milwaukee, WI | 2 | $1.5 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 4 | $1.5 million | 0 | $0 |
| Northwestern University | Chicago, IL | 2 | $1.3 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 3 | $1.3 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 1 | $1.3 million | 0 | $0 |
| Boston Medical Center | Boston, MA | 3 | $1.2 million | 0 | $0 |
| Baystate Medical Center, Inc. | Springfield, MA | 1 | $1.1 million | 0 | $0 |
| Sri International | Menlo Park, CA | 1 | $1.1 million | 0 | $0 |
| Denver Health and Hospital Authority | Denver, CO | 1 | $1.1 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 1 | $1 million | 0 | $0 |
| Riboscience, LLC | Palo Alto, CA | 1 | $995,102 | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 1 | $941,278 | 0 | $0 |
| Cornell University | Ithaca, NY | 2 | $917,103 | 0 | $0 |
| University of Illinois at Urbana-Champaign | Urbana, IL | 1 | $776,341 | 0 | $0 |
| University of Kansas Center for Research Inc | Lawrence, KS | 1 | $753,221 | 0 | $0 |
| Research Triangle Institute | Research Triangle Park, NC | 1 | $732,149 | 0 | $0 |
| East Tennessee State University | Johnson City, TN | 1 | $704,290 | 0 | $0 |
| Zymeron Corporation | Durham, NC | 2 | $700,000 | 0 | $0 |
| The University of Central Florida Board of Trustees | Orlando, FL | 2 | $689,619 | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 2 | $668,397 | 0 | $0 |
| University of South Florida | Tampa, FL | 1 | $663,802 | 0 | $0 |
| North Jersey Aids Alliance ,inc. (njcri) | Newark, NJ | 1 | $583,902 | 0 | $0 |
| Kaiser Foundation Research Institute | Oakland, CA | 1 | $573,066 | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 1 | $525,951 | 0 | $0 |
| Duquesne University | Pittsburgh, PA | 1 | $507,121 | 0 | $0 |
| Clemson University | Clemson, SC | 1 | $498,000 | 0 | $0 |
| Healthpartners Institute | Bloomington, MN | 1 | $491,236 | 0 | $0 |
| Rhode Island Hospital | Providence, RI | 1 | $487,686 | 0 | $0 |
| SUNY at Albany | Albany, NY | 1 | $481,269 | 0 | $0 |
| University of Notre Dame | Notre Dame, IN | 1 | $430,375 | 0 | $0 |
| University of Bristol | Bristol | 1 | $427,571 | 0 | $0 |
| Washington State University | Pullman, WA | 1 | $406,490 | 0 | $0 |
| Pathovacs, Inc. | Ames, IA | 1 | $393,833 | 0 | $0 |
| University of Georgia Research Foundation Inc | Athens, GA | 1 | $366,441 | 0 | $0 |
| Fisher Bioservices, Inc. | Rockville, MD | 1 | $304,084 | 0 | $0 |
| Avantgen, Inc. | San Diego, CA | 1 | $300,000 | 0 | $0 |
| Neuimmune Biologics, Inc. | Sykesville, MD | 1 | $300,000 | 0 | $0 |
| Luna Labs Usa, LLC | Charlottesville, VA | 1 | $299,997 | 0 | $0 |
| Giner, Inc. | Newton, MA | 1 | $299,979 | 0 | $0 |
| Arete Biosciences | Chicago, IL | 1 | $299,961 | 0 | $0 |
| Phoenix Biosystem, Inc. | Pleasanton, CA | 1 | $299,957 | 0 | $0 |
| Esper Biosciences, Inc. | Ithaca, NY | 1 | $299,889 | 0 | $0 |
| Big Eye Diagnostics, Inc. | San Diego, CA | 1 | $299,659 | 0 | $0 |
| Purdue University | West Lafayette, IN | 1 | $289,274 | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 95 | $66,744,750 | 0 | $0 |
| 2024 | 103 | $62,034,729 | 0 | $0 |
| 2023 | 109 | $72,284,426 | 0 | $0 |
| 2022 | 130 | $80,864,558 | 0 | $0 |
| 2021 | 162 | $103,025,862 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.